Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits

Medicine & Life Sciences

• Sodium-Glucose Transporter 2 Inhibitors 100%
• Symporters 94%
• Canagliflozin 60%
• Type 2 Diabetes Mellitus 46%
• Bone and Bones 41%
• Kidney 37%
• 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 23%
• empagliflozin 23%
• Skeleton 15%
• Bone Density 13%
• calcium phosphate 8%
• Bone Fractures 8%
• Bone Remodeling 7%
• Hypotension 7%
• Blood Glucose 6%
• Weight Loss 6%
• Accidental Falls 6%
• Homeostasis 5%
• Placebos 5%
• Pharmaceutical Preparations 3%
• Therapeutics 1%